Theralase Releases Q122 Interim Financial Statements

Rhea-AI Summary

Theralase Technologies Inc. (TLTFF) reported its 1Q2022 financial results, showing a 70% increase in total revenue to $211,662 compared to $124,783 in 2021. Gross margin improved to 43%, while net loss rose to $1,701,489, an 85% increase year-over-year largely due to elevated R&D expenses. The company's Fast Track Designation from the FDA for its Study II allows for frequent communication on trials. Despite setbacks from the COVID-19 pandemic, patient enrollment in clinical studies is progressing, with new anti-cancer indications being explored and COVID-19 vaccine development ongoing.

Positive

• Total revenue increased by 70% to $211,662.
• Gross margin improved from 40% to 43% of revenue.
• Decreased selling expenses by 8% to $87,640.
• Fast Track Designation from FDA supports timely data collection for clinical approval.
• Progress in patient enrollment with 12 clinical study sites active.

Negative

• Net loss increased by 85% to $1,701,489.
• R&D expenses surged by 120% due to Study II costs.
• COVID-19 pandemic continues to delay patient enrollment in clinical studies.

TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase^® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 1Q2022 condensed interim consolidated Financial Statements (“Financial Statements”).

Financial Highlights:

For the three-month period ended March 31^st:

Audited Consolidated Statements of Operations In Canadian Dollars	2022		2021		% Change
Revenue
Canada	179,145		104,406		72%
United States	32,517		20,377		60%
Total Revenue	211,662		124,783		70%
Cost of Sales	120,430		74,463		62%
Gross Margin	91,232		50,320		81%
Gross Margin as a percentage of sales	43%		40%
Operating Expenses
Selling Expenses	87,640		95,780		-8%
Administrative Expenses	418,087		418,454		1%
Research and Development Expenses – CLT Division	72,832		54,616		33%
Research and Development Expenses – ACT Division	1,225,203		534,951		129%
Other(1)	-11,040		-134,388		-92%
Total Operating Expenses	1,792,721		969,413		85%
Net Loss	-1,701,489		-919,093		85%

      (1)   Other represents gain from legal settlement, (gain) loss on foreign exchange, interest accretion on lease liabilities and interest income

Total revenue increased 70%, year over year, and is primarily attributed to the anticipated Canadian and US economic recovery from the COVID-19 pandemic in 2020 and 2021.

Cost of sales for the three-month period ended March 31, 2022 was $120,430 or 57% of revenue resulting in a gross margin of $91,232 or 43% of revenue. In comparison, the cost of sales in 2021 was $74,463 or 60% of revenue resulting in a gross margin of $50,320 or 40% of revenue. The gross margin increase, as a percentage of sales, year over year, is primarily attributed to a decrease in labour and material costs.

Selling expenses for the three-month period ended March 31, 2022, decreased to $87,640, from $95,780 in 2021, an 8% decrease. The decrease in selling expenses is primarily attributed to the COVID-19 pandemic, resulting in reduced advertising (48%), and salaries (8%).

Administrative expenses for the three-month period ended March 31, 2022, decreased slightly to $418,087 from $418,454 in 2021, a 1% decrease. The decrease in administrative expenses is primarily attributed to decreased spending in administrative salaries (4%) and insurance expenses (8%). Stock based compensation expense decreased 61% in 2022 due to a reduction in stock options granted.

Net research and development expenses for the three-month period ended March 31, 2022, increased to $1,298,035 from $589,567 in 2021, a 120%. The increase in research and development expenses for the three-month period ended March 31, 2022, is primarily attributed to the costs related to Study II. Research and development expenses represented 72% of the Company’s operating expenses and represents investment into the research and development of the Company’s ACT technology.

The net loss for the three-month period ended March 31, 2022 was $1,701,489 which included $99,600 of net non-cash expenses (i.e.: amortization, stock-based compensation expense and foreign exchange gain/loss). This compared to a net loss in 2021 of $919,093 which included $179,925 of net non-cash expenses. The ACT division represented $1,436,985 of this loss (84%) for the three-month period ended March 31, 2022.

The increase in net loss is primarily attributed to Increased spending in research and development expenses in Study II.

Operational Highlights:

1. Break Through Designation Update. In 2020, the FDA granted Theralase^® Fast Track Designation (“FTD”) for Study II. As a Fast Track designee, Theralase^® has access to early and frequent communications with the FDA to discuss Theralase^®’s development plans and ensure the timely collection of clinical data to support the approval process.  FTD can also lead to Break Through Designation (“BTD”), Accelerated Approval (“AA”) and/or Priority Review, if certain criteria are met, which the FDA has previously defined to the Company for BTD to represent a complete clinical dataset on approximately 20 to 25 patients enrolled, treated and followed-up, who demonstrate significant safety and efficacy clinical outcomes.

In 2021, Theralase^® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 day assessment for 25 patients, expected in 4Q2022, subject to the Clinical Study Sites (“CSS”) availability to complete all required assessments.

2. COVID-19 Pandemic Update. In the ACT division, the Company continues to experience delays in patient enrollment and treatment rates in Study II due to the ongoing COVID-19 pandemic; however, these rates have improved as Canada and the US commence their recovery from the business and economic impacts of the COVID-19 pandemic.

In the CLT division, the Company continues to experience variations in sales and the timing of these sales due to the ongoing COVID-19 pandemic and has taken actions to minimize expenses by eliminating non-essential personnel and imposing a temporary hiring freeze commencing in March 2020. The Company lifted the temporary hiring freeze in 4Q2021, now that the Canadian and United States (“US”) economies have started to demonstrate a sustainable business and economic recovery from COVID-19.

3. Clinical study site status and update. The Company has successfully launched five CSS in Canada and seven CSSs in the US that are open for patient enrollment and treatment for a total of 12 CSSs.

To date, the phase II NMIBC clinical study has enrolled and provided the primary study treatment for 38 patients (including three patients from Phase Ib study treated at the Therapeutic Dose) for a total of 41 patients.

An analysis of Evaluable Patients (defined as patients who have been evaluated by the principal investigator and thus excludes data pending), Study II clinical data provides the following interim analysis:

Assessment	90 Day	180 Day	270 Day	360 Day	450 Day
Complete Response (“CR”)	46%	50%	39%	22%	23%
Partial Response (“PR”)	22%	22%	8%	17%	9%
Total Response (“CR + PR”)	68%	72%	46%	39%	32%

For all Evaluable Patients, who achieved a CR at 90 days, 88% demonstrate that CR at 180 days, 69% at 270 days, 50% at 360 days and 56% at 450 days, demonstrating a strong duration of complete response.

Note: The current interim data analysis presented above should be read with caution, as the clinical data is interim in its presentation, as Study II is ongoing and new clinical data collected may or may not continue to support the current trends, with significant data still pending.

For a more comprehensive analysis of the interim data please refer to Managements Discussion and Analysis (“MD&A”) for the three-month period ended March 31, 2022.

4.  Additional cancer indications. The Company has demonstrated significant anti-cancer efficacy of Rutherrin^®, when activated by laser light or radiation treatment across numerous preclinical models; including: Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”). The Company has commenced Non - Good Laboratory Practices (“GLP”) toxicology studies with Rutherrin^® in animals to help determine the maximum recommended human dose of the drug when administered systemically into the human body, via intravenous injections. Theralase plans to commence GLP toxicology studies in animals in 4Q2022.

5. COVID-19 Research Update. In April 2021, Theralase^® executed a Collaborative Research Agreement (“CRA”) with the National Microbiology Laboratory, Public Health Agency of Canada (“PHAC”) for the research and development of a Canadian-based SARS-CoV-2 (“COVID-19”) vaccine. Under the terms of the agreement, Theralase^® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase^®’s patented PDC and then light activating it with Theralase^®’s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. This inactivated virus would then be purified and used to inoculate naive animals followed by challenge with the SARS-CoV-2 virus, to ascertain the efficacy of the vaccine. The project is entitled, “Photo Dynamic Compound Inactivation of SARS-CoV-2 Vaccine” and commenced in mid-April 2021.

In February, 2022 Theralase^® reported that PHAC had demonstrated that light-activated TLD-1433, was effective in rapidly inactivating the SARS-CoV-2 virus by up to 99.99%, compared to control in an in vitro study. Further research is required to confirm these findings.

These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase^® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus, which is expected to commence in 2Q2022 and be completed by 4Q2022.

Note: The Company does not claim or profess that they have the ability to treat, cure or prevent the contraction of the COVID-19 coronavirus.

About Study II
Study II utilizes the therapeutic dose of TLD-1433 (0.70 mg/cm²) activated by the proprietary TLC-3200 medical laser system. Study II is focused on enrolling and treating approximately 100 to 125 BCG-Unresponsive NMIBC Carcinoma In-Situ (“CIS”) patients in up to 15 Clinical Study Sites (“CSS”) located in Canada and the United States.

About TLD-1433
TLD-1433 is a patented PDC with over 10 years of published peer reviewed preclinical research and is currently under investigation in Study II.

About Theralase^® Technologies Inc.
Theralase^® is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedar.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations and a COVID-19 vaccine. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions including statements related to the current expectations of Company's management for future research, development and commercialization of the Company’s Photo Dynamic Compounds and their drug formulations, including preclinical research, clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to: adequately fund, and secure the requisite regulatory approvals to successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company’s operations may not be available or may not be available on terms that are commercially favorable to the Company, the risk that the Company’s drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company’s fails to comply with the term of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these forward-looking statements which are not a guarantee of future performance. There can be no assurance that forward looking statements will prove to be accurate as such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.

Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey CPA, Chief Financial Officer
khachey@theralase.com
www.theralase.com

FAQ

What were Theralase's total revenues for 1Q2022?

Theralase reported total revenues of $211,662 for the three-month period ended March 31, 2022.

How much did Theralase's net loss increase in 1Q2022?

The net loss for Theralase increased to $1,701,489, an 85% rise compared to the previous year.

What percentage did Theralase's gross margin improve in 1Q2022?

Theralase's gross margin improved from 40% in 2021 to 43% in 2022.

How has COVID-19 impacted Theralase's operations?

COVID-19 has caused delays in patient enrollment and treatment rates for Theralase's clinical studies.

What designation has Theralase received from the FDA?

Theralase received Fast Track Designation from the FDA for its Study II.